Patents by Inventor Evelyn A. Kurt-Jones

Evelyn A. Kurt-Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds for modulating TLR2
    Patent number: 9271972
    Abstract: The present invention is directed to methods, kits, and uses of inhibitors of LCMV mediated NF-?B activation to treat viral infections and inflammatory conditions.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: March 1, 2016
    Assignee: University of Massachusetts
    Inventors: Robert W. Finberg, Evelyn A. Kurt-Jones, Shenghua Zhou
  • COMPOUNDS FOR MODULATING TLR2
    Publication number: 20140296219
    Abstract: The present invention is directed to methods, kits, and uses of inhibitors of LCMV mediated NF-?B activation to treat viral infections and inflammatory conditions.
    Type: Application
    Filed: November 14, 2013
    Publication date: October 2, 2014
    Applicant: UNIVERSITY OF MASSACHUSETTS
    Inventors: Robert W. Finberg, Evelyn A. Kurt-Jones, Shenghua Zhou
  • Modulation of HSV infection
    Patent number: 8748403
    Abstract: Toll-like receptor 2 (TLR2) has been found to mediate certain effects of HSV infection, particularly in neonates. Compounds that decrease TLR2 expression or activity are useful for ameliorating such deleterious effects.
    Type: Grant
    Filed: January 21, 2005
    Date of Patent: June 10, 2014
    Assignee: University of Massachusetts
    Inventors: Evelyn A. Kurt-Jones, Robert W. Finberg
  • Compounds for modulating TLR2
    Patent number: 8609663
    Abstract: The present invention is directed to methods, kits, and uses of inhibitors of LCMV mediated NF-?B activation to treat viral infections and inflammatory conditions.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: December 17, 2013
    Assignee: University of Massachusetts
    Inventors: Robert W. Finberg, Evelyn A. Kurt-Jones, Shenghua Zhou
  • Pancreatitis
    Patent number: 8231861
    Abstract: The present invention provides methods of identifying candidate therapeutic agents for use in the treatment of acute pancreatitis.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: July 31, 2012
    Assignee: University of Massachusetts
    Inventors: Ashok Saluja, Rifat Sharif, Evelyn A. Kurt-Jones, Robert W. Finberg
  • COMPOUNDS FOR MODULATING TLR2
    Publication number: 20110152251
    Abstract: The present invention is directed to methods, kits, and uses of inhibitors of LCMV mediated NF-?B activation to treat viral infections and inflammatory conditions.
    Type: Application
    Filed: November 17, 2010
    Publication date: June 23, 2011
    Applicant: UNIVERSITY OF MASSACHUSETTS
    Inventors: Robert W. Finberg, Evelyn A. Kurt-Jones, Shenghua Zhou
  • Antibodies to toll-like receptor-2
    Patent number: 7759465
    Abstract: It has been found that Toll-like receptor 1 and Toll-like receptor 2 (TLR2) physically interact. Antibodies that specifically bind to TLR2 and selectively inhibit induction of cytokines are also described. The invention relates to specific antibodies that selectively bind to TLR2, and to methods of identifying compounds that selectively interfere with signaling through TLR1/TLR2 complexes.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: July 20, 2010
    Assignee: University of Massachusetts
    Inventors: Evelyn A. Kurt-Jones, Robert W. Finberg
  • SELECTIVE INHIBITION OF TOLL-LIKE RECEPTOR-2
    Publication number: 20090087430
    Abstract: It has been found that Toll-like receptor 1 and Toll-like receptor 2 (TLR2) physically interact. Antibodies that specifically bind to TLR2 and selectively inhibit induction of cytokines are also described. The invention relates to specific antibodies that selectively bind to TLR2, and to methods of identifying compounds that selectively interfere with signaling through TLR1/TLR2 complexes.
    Type: Application
    Filed: June 6, 2008
    Publication date: April 2, 2009
    Inventors: Evelyn A. Kurt-Jones, Robert W. Finberg
  • Selective inhibition of toll-like receptor-2
    Patent number: 7388080
    Abstract: It has been found that Toll-like receptor 1 and Toll-like receptor 2 (TLR2) physically interact. Antibodies that specifically bind to TLR2 and selectively inhibit induction of cytokines are also described. The invention relates to specific antibodies that selectively bind to TLR2, and to methods of identifying compounds that selectively interfere with signaling through TLR1/TLR2 complexes.
    Type: Grant
    Filed: August 20, 2004
    Date of Patent: June 17, 2008
    Assignee: University of Massachusetts
    Inventors: Evelyn A. Kurt-Jones, Robert W. Finberg
  • Pancreatitis
    Publication number: 20080112887
    Abstract: The present invention provides methods of identifying candidate therapeutic agents for use in the treatment of acute pancreatitis.
    Type: Application
    Filed: November 19, 2004
    Publication date: May 15, 2008
    Inventors: Ashok Saluja, Rifat Sharif, Evelyn A. Kurt-Jones, Robert W. Finberg
  • Use of agents which bind G proteins for treating septic shock
    Patent number: 6949507
    Abstract: The present invention provides for the use of G protein binding agents for prophylactic and/or therapeutic treatments of septic shock. The present invention provides methods of using agents which bind G protein to treat a subject having or susceptible to septic shock. The present invention further pertains to compositions for treating a subject for septic shock. The composition includes an effective amount of a G protein binding agent and, optionally, an antibiotic and a pharmaceutically acceptable carrier. Other aspects of the invention include packaged agents which bind G proteins for treating septic shock.
    Type: Grant
    Filed: October 29, 2002
    Date of Patent: September 27, 2005
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Robert W. Finberg, Evelyn A. Kurt-Jones, Keith R. Solomon
  • Modulation of HSV infection
    Publication number: 20050164172
    Abstract: Toll-like receptor 2 (TLR2) has been found to mediate certain effects of HSV infection, particularly in neonates. Compounds that decrease TLR2 expression or activity are useful for ameliorating such deleterious effects.
    Type: Application
    Filed: January 21, 2005
    Publication date: July 28, 2005
    Inventors: Evelyn Kurt-Jones, Robert Finberg
  • Selective inhibition of toll-like receptor-2
    Publication number: 20050074823
    Abstract: It has been found that Toll-like receptor 1 and Toll-like receptor 2 (TLR2) physically interact. Antibodies that specifically bind to TLR2 and selectively inhibit induction of cytokines are also described. The invention relates to specific antibodies that selectively bind to TLR2, and to methods of identifying compounds that selectively interfere with signaling through TLR1/TLR2 complexes.
    Type: Application
    Filed: August 20, 2004
    Publication date: April 7, 2005
    Inventors: Evelyn Kurt-Jones, Robert Finberg
  • Use of agents which bind G proteins for treating septic shock
    Patent number: 6583110
    Abstract: The present invention provides for the use of G protein binding agents for prophylactic and/or therapeutic treatment of septic shock. The present invention provides methods of using agents which bind G protein to treat a subject having or susceptible to septic shock. The present invention further pertains to compositions for treating a subject for septic shock. The composition includes an effective amount of a G protein binding agent such as mastoparan and, optionally, an antibiotic and a pharmaceutically acceptable carrier. Other aspects of the invention include packaged agents which bind G proteins for treating septic shock.
    Type: Grant
    Filed: May 23, 2000
    Date of Patent: June 24, 2003
    Inventors: Robert W. Finberg, Evelyn A. Kurt-Jones, Keith R. Solomon
  • Use of gents which bind G proteins for treating septic shock
    Publication number: 20030069185
    Abstract: The present invention provides for the use of G protein binding agents for prophylactic and/or therapeutic treatments of septic shock. The present invention provides methods of using agents which bind G protein to treat a subject having or susceptible to septic shock. The present invention further pertains to compositions for treating a subject for septic shock. The composition includes an effective amount of a G protein binding agent and, optionally, an antibiotic and a pharmaceutically acceptable carrier. Other aspects of the invention include packaged agents which bind G proteins for treating septic shock.
    Type: Application
    Filed: October 29, 2002
    Publication date: April 10, 2003
    Applicant: Dana-Farber Cancer Institute
    Inventors: Robert W. Finberg, Evelyn A. Kurt-Jones, Keith R. Solomon